Beximco Pharma - eine Perle aus Bangladesch? (Seite 33)

[Crsus]

Aktueller Kurs von Beximco ex 15 % Stockdividende 152,40 Taka = 1,75 Euro

[Crsus]

BEXIMCO PHARMACEUTICALS LTD.



14 May, 2010

Beximco Announces Financial Results for the First Quarter of 2010

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces its unaudited financial results for the three month period ended 31 March 2010. The information set out below has been released to the Dhaka and Chittagong Stock Exchanges in compliance with the requirements from the Bangladesh SEC.

The accounts can be viewed at the Company's website: www.beximcopharma.com

For further enquiries please contact:



Beximco Pharma

Nazmul Hassan MP, Managing Director
Tel: [phone], ext.2080



Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel: [phone], Ext 1140



Libertas Capital Corporate Finance

Jakob Kinde / Anthony Rowland
Tel: [phone]

Financial Dynamics

Jonathan Birt / Susan Quigley
Tel: [phone]

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.



The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.



END







Beximco Pharmaceuticals Ltd.

Balance Sheet (Un-audited)

As at 31 March, 2010







Amount in Thousand BDT



As at 31 March
2010
As at 31 December
2009

ASSETS





Non-Current Assets
13,294,307
12,975,195

Property, Plant and Equipment- Carrying Value
13,278,611
12,966,587

Intangible Assets
12,814
5,726

Investment in Shares
2,882
2,882








Current Assets
6,827,886
6,916,738

Inventories
1,922,640
1,722,953

Spares & Supplies
285,525
242,035

Accounts Receivable
741,597
694,112

Loans, Advances and Deposits
781,513
699,204

Short Term Investment
1,634,133
2,500,000

Cash and Cash Equivalents
1,462,478
1,058,434

TOTAL ASSETS
20,122,193
19,891,933








SHAREHOLDERS' EQUITY AND LIABILITIES





Shareholders' Equity
13,153,669
10,885,707

Issued Share Capital
1,673,185
1,511,493

Share Premium
3,378,058
1,489,750

Excess of Issue Price over Face Value of GDRs
1,689,637
1,689,637

Capital Reserve on Merger
294,951
294,951

Revaluation Surplus
1,610,659
1,617,362

Retained Earnings
4,507,179
4,282,514








Non-Current Liabilities
4,784,902
6,684,775

Long Term Borrowing-Net off Current Maturity (Secured)
1,960,672
1,924,933

Fully Convertible, 5% Dividend, Preference Share
2,050,000
4,100,000

Liability for Gratuity & WPPF
321,702
307,426

Deferred Tax Liability
452,528
352,416








Current Liabilities and Provisions
2,183,622
2,321,451

Short Term Borrowing
1,479,941
1,451,326

Long Term Borrowing-Current Maturity
281,501
308,820

Creditors and other Payables
349,638
409,898

Accrued Expenses
62,437
79,095

Dividend Payable
1,521
1,728

Income Tax Payable
8,584
70,584








TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY
20,122,193
19,891,933








Beximco Pharmaceuticals Ltd.

Profit and Loss Account (Un-audited)

For the 1st Quarter Ended 31 March, 2010





Amount in Thousand BDT



1st Quarter Ended
31 March, 2010
1st Quarter Ended
31 March, 2009

Net Sales Revenue
1,326,601
1,088,805








Cost of Goods Sold :
(694,479)
(568,486)

Materials
(507,471)
(435,795)

Factory Overhead
(90,606)
(79,720)

Depreciation
(96,402)
(52,971)








Gross Profit
632,122
520,319








Operating Expenses :
(297,959)
(299,044)

Administrative Expenses
(43,107)
(47,836)

Selling and Distribution Expenses
(254,852)
(251,208)








Profit from Operations
334,163
221,275








Other Income
194,916
5,050

Finance Cost
(92,602)
(67,447)

Preference Share Dividend
(102,500)
-

Profit Before Contribution to WPPF
333,977
158,878

Contribution to Workers' Profit Participation/ Welfare





Funds
(15,904)
(7,566)








Profit Before Tax
318,073
151,312

Income Tax
(100,111)
(27,236)

Net Profit After Tax
217,962
124,076








Earnings Per Share (EPS)
1.30
0.82

Number of shares used to compute EPS
167,318,487
151,149,296








Beximco Pharmaceuticals Ltd.

Cash Flow Statement (Un-audited)

For the 1st Quarter Ended 31 March, 2010





Amount in Thousand BDT



1st Quarter Ended
31 March, 2010
1st Quarter Ended
31 March, 2009

Cash Flows from Operating Activities :





Cash Receipts from Customers and Others
1,474,032
985,824

Cash Paid to Suppliers and Employees
(1,288,152)
(873,914)

Cash Generated from Operations
185,880
111,910








Interest Paid
(92,602)
(67,447)

Income Tax Paid
(62,000)
(16,676)

Net Cash Generated from Operating Activities
31,278
27,787








Cash Flows from Investing Activities :





Acquisition of Property, Plant and Equipment
(420,341)
(67,240)

Intangible Assets
(7,088)
-

Short Term Investment
865,867



Net cash Used in Investing Activities
438,438
(67,240)








Cash Flows from Financing Activities :





Net Increase / (Decrease) in Long Term Borrowings
8,420
(40,973)

Net Increase / (Decrease) in Short Term Borrowing
28,615
64,160

Preference Share Dividend
(102,500)



Ordinary Share Dividend
(207)
(857)








Net Cash Generated from Financing Activities
(65,672)
22,330

Increase/(Decrease) in Cash and Cash Equivalents
404,044
(17,123)

Cash and Cash Equivalents at Beginning of Period
1,058,434
73,648








Cash and Cash Equivalents at End of Period
1,462,478
56,525








Beximco Pharmaceuticals Limited

Statement of Changes in Equity (Unaudited)



For the 1st Quarter Ended 31 March, 2009

Amount in Thousand BDT





Share Capital
Share Premium
Excess of Issue Price over Face Value of GDRs
Capital Reserve
Revaluation Surplus
Retained Earnings
Total

Opening Balance on 01.01.2009

1,259,577
1,489,750
1,689,637
294,951
1,711,175
4,005,112
10,450,202

Net Profit for the Period


-
-
-
-
-
124,076
124,076

Adjustment for Depreciation on Revalued Assets


-
-
-
-
(7,634)
7,634
-

At the end of 31 March 2009
Tk.
1,259,577
1,489,750
1,689,637
294,951
1,703,541
4,136,822
10,574,278




















Total Number of shares at 31 March 2009














151,149,296

Net Asset Value Per Share (NAVPS) 31 March 2009














69.96






For the 1st Quarter Ended 31 March, 2010

Amount in Thousand BDT





Share Capital
Share Premium
Excess of Issue Price over Face Value of GDRs
Capital Reserve
Revaluation Surplus
Retained Earnings
Total

Opening Balance on 01.01.2010


1,511,493
1,489,750
1,689,637
294,951
1,617,362
4,282,514
10,885,707

Net Profit for the Period


-
-
-
-
-
217,962
217,962

Preference Share Converted into Ordinary Share


161,692










161,692

Premium on Conversion of Preference Share




1,888,308








1,888,308

Adjustment for Depreciation on Revalued Assets


-
-
-
-
(6,703)
6,703
-

At the end of 31 March 2009
Tk
1,673,185
3,378,058
1,689,637
294,951
1,610,659
4,507,179
13,153,669




















Total Number of shares at 31 March 2010














167,318,487

Net Asset Value Per Share (NAVPS) 31 March 2010














78.61

[Crsus]

Aktueller Kurs von Beximco 171,00 Taka = 1,95 Euro

Unglaublich, dass der Euro sogar gegenüber der Währung von Bangladesch dermaßen fällt ...

[Crsus]

BEXIMCO PHARMACEUTICALS LTD.

29th April, 2010

PRICE SENSITIVE INFORMATION



Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces information for Shareholders of the Company that the Board of Directors at their meeting held on 29th April, 2010 has decided the following:



1. To recommend the approval of the Financial Statements for the year ended 31 December 2009
:
The results are expected to be announced week commencing Tuesday 4th May 2010








2. Date & Time of 34th AGM of the Company for the year 2009
:
15th June, 2010 at 10.00 a.m.








3 Venue of AGM


:
Beximco Industrial Park, Sarabo, Kashimpur, Gazipur, Bangladesh








4. Proposed Dividend for year ended 31 December 2009
:
15% Stock dividend (i.e.15 shares for every 100 shares held)








5. Record date
:
19th May, 2010








6. Net Asset Value as at 31 December 2009
:
Taka 10,885,706,614








7. Net Asset Value per share as at 31 December 2009
:
Taka 72.02








8. Net Profit After Tax for the year ended 31 December 2009
:
Taka 624,740,307








9. Earnings per share (EPS) for the year ended 31 December 2009
:
Taka 4.13








10. Net Operating Cash Flow per share for the year ended 31 December 2009
:
Taka 3.45

[putzig]

während des Tages 193

[Crsus]

Allzeit-Hoch !!!

Aktueller Kurs von Beximco 191,50 Taka = 2,06 Euro

Es gibt zwar keine News, aber da der Kursanstieg an der Heimatbörse bei stark gestiegenen Umsätzen stattfindet, denke ich, dass man dort schon einen Grund für die Käufe kennt.

[putzig]

Antwort auf Beitrag Nr.: 39.185.477 von Crsus am 21.03.10 13:29:39

heute 188 Taka. Gibts neu Nachrichten ? Quartalszahlen ?, oder warum auf einmal der Anstieg ??

[Crsus]

Heute mal wieder ein richtig guter Tag für Beximco:

Aktueller Kurs von Beximco 180,00 Taka = 1,92 Euro , Umsatz 3.746.700 Stück.

Am Freitag in London 65.863 Stück Umsatz, letzter Kurs war 0,43 Euro, Abgeld also ca. 78 %.

[Crsus]

Aktueller Kurs von Beximco fast unverändert bei 170,20 Taka = 1,80 Euro , Umsatz 458.700 Stück.

Am Freitag in London 254.860 Stück Umsatz, letzter Kurs war 0,44 Euro, Abgeld also ca. 76 %.

[Crsus]

Aktueller Kurs von Beximco 169,40 Taka = 1,80 Euro